We aimed to investigate whether NLR family, pyrin domain containing 3 (NLRP3) polymorphisms are associated with the response to interferon-beta (IFNβ) in multiple sclerosis (MS) patients. A total of 14 NLRP3 polymorphisms were genotyped in a cohort of 665 relapsing-remitting MS patients recruited across 5 centers and classified into responders and non-responders according to clinical-radiological criteria after 1 year of IFNβ treatment. A meta-analysis failed to demonstrate significant associations between the response to IFNβ and NLRP3 polymorphisms. These findings do not support a role of polymorphisms located in the NLRP3 gene and the response to IFNβ in MS patients.
GuardaGBraunMStaehliFet al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity2011; 34: 213–223.
2.
MalhotraSRíoJUrcelayEet al. NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis. Brain2015; 138(Pt3): 644–652.
3.
PolmanCHReingoldSCBanwellBet al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol2011; 69: 292–302.
4.
RíoJCastillóJRoviraAet al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler2009; 15: 848–853.
5.
PurcellSNealeBTodd-BrownKet al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet2007; 81: 559–575.
6.
MantelNHaenszelW.Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst1959; 22: 719–748.
